Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy Rating

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other analysts also recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Bank of America increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday. Guggenheim increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Cantor Fitzgerald increased their price target on Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Trading Down 4.1 %

Shares of Amicus Therapeutics stock opened at $9.68 on Friday. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The firm has a market cap of $2.89 billion, a PE ratio of -28.47 and a beta of 0.68. The business’s fifty day moving average is $11.00 and its two-hundred day moving average is $10.61. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 30,401 shares of company stock worth $352,038. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics in the third quarter valued at about $26,000. Hazlett Burt & Watson Inc. increased its holdings in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the period. Blue Trust Inc. increased its holdings in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares during the period. Arcadia Investment Management Corp MI acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.